Phio Pharmaceuticals’ Stock Jumps After Company Unveils Positive Data From “in Vivo” Studies Showing Strong Antitumoral Efficacy

Phio Pharmaceuticals Corp’s stock (NASDAQ: PHIO) almost doubles as investors get to know the successful  INTASYL pipeline program’s improvement in treating tumors. Friday’s opening market will probably repeat the same scenario or even continue PHIO’s rocketing. Fortunately, its Q1 2020 assets surged by approximately $6 million along with total equity but liabilities could only climb by almost $30 thousand. Additionally, Q1 2020 total debt has shrunk quarterly by $26 thousand.

For the long term, PHIO has been falling and net income has not been so well because of costly research and development. Since Q1 2019 there has been no revenue. The upcoming Q2 report might have positive earnings and revenue if the pipeline program is completely developed.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life

Alex Krakowsky has 979 posts and counting. See all posts by Alex Krakowsky